New shingles vaccine trial aims to protect millions over 40
NCT ID NCT06932523
First seen Jan 08, 2026 · Last updated May 14, 2026 · Updated 15 times
Summary
This study tests a new shingles vaccine in 645 healthy adults aged 40 and up. Participants receive two doses to see if the vaccine is safe and triggers a strong immune response. The goal is to find a well-tolerated vaccine that prevents shingles in this age group.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HERPES ZOSTER (HZ) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Hubei Provincial Center for Disease Control and Prevention
RECRUITINGWuhan, Hubei, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.